These are projects commissioned by NICE in relation to the appraisal of specific technologies under the Multiple Technology Appraisal (MTA) and Single Technology Appraisal (STA) programmes.
- Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine
- Age-related macular degeneration – ranibizumab and pegaptanib
- Ankylosing spondylitis – adalimumab, etanercept and infliximab
- Breast cancer – lapatinib
- Crohn’s disease – adalimumab and infliximab
- Colorectal cancer – cetuximab
- Diabetes – dapagliflozin
- Diabetes – liraglutide
- Lung cancer – erlotinib
- Lupus – belimumab
- Macular oedema – bevacizumab
- Myelodysplastic syndromes – azacitidine
- Neuroblastoma – dinutuximab beta
- Osteoporosis – alendronate, etidronate, risedronate, raloxifene, teriparatide and strontium ranelate
- Prostate cancer – degarelix
- Renal cell carcinoma – bevacizumab, sorafenib, sunitinib and temsirolimus
- Rheumatoid arthritis – adalimumab, etanercept and infliximab
- Rheumatoid arthritis – adalimumab, etanercept and infliximab (sequential use)
- Rheumatoid arthritis – adalimumab, etanercept, inflizimab, certolizumab pegol, golimumab, abatacept and tocilizumab
- Rheumatoid arthritis – tocilizumab